U.S. Government Awards $1 Million Grant to British PowderJect Pharmaceuticals for Development of HIV Vaccine
The U.S. National Institute of Allergy and Infectious Diseases, in association with the University of Pittsburgh, on Thursday awarded a one-year, $1 million grant to British biotech company PowderJect Pharmaceuticals to help fund the development of a powdered DNA-based HIV vaccine, Reuters reports. Researchers believe that the needle-free system may be effective in delivering a DNA vaccine, which would stimulate an immune response to the HIV genetic information. Research on the vaccine is still in the pre-clinical stage and "a number of years away" from marketing (Reuters, 10/11).This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.